Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
Status:
Recruiting
Trial end date:
2024-08-20
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of Lenvatinib plus
Sintilimab in patients with advanced liver cancer progressed after treatment with immune
checkpoint inhibitors.